YOUR CONDITION, EXPLAINED
Malignant Neoplasms of the Respiratory System VA Disability Rating
The VA rates Malignant Neoplasms of the Respiratory System under diagnostic code 6819, in 38 CFR § 4.97 (respiratory system), and the schedule provides a single evaluation under it: 100%.
Free · No account needed
Save your Malignant Neoplasms of the Respiratory System guide
Email yourself this Malignant Neoplasms of the Respiratory System guide so the rating criteria, evidence checklist, and preparation tips are easy to find later.
A CLEARER PATH FORWARD
Make sense of your next step.
01Understand the rating02Know what to gather03Plan your preparationTHE ESSENTIALS
How the VA rates Malignant Neoplasms of the Respiratory System
DC 6819 is the respiratory system's cancer code, and it pays one evaluation: 100 percent. Its whole criterion is its own title — neoplasms, malignant, any specified part of respiratory system exclusive of skin growths — so site, stage and treatment do not move the percentage while the code applies. Two rules decide everything around it. The note ends the 100 percent not when treatment ends but at a mandatory VA examination six months after treatment is discontinued, and where there has been no local recurrence or metastasis the rating is then built on the residuals. And 38 CFR 4.96(a) says that where there is lung or pleural involvement a DC 6819 evaluation is not combined with the other respiratory codes: one rating is assigned, under whichever code reflects the predominant disability.
DC 6819 states one criterion and one evaluation: neoplasms, malignant, any specified part of respiratory system exclusive of skin growths — 100 percent. There is no second tier and no severity scale, and the code does not distinguish by organ; 38 CFR 4.97's tables run from the nose and throat through the trachea and bronchi to the lungs, and any specified part of that system is covered. Skin growths are the one exclusion the code names. Its note is what decides how long the evaluation lasts. A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of 38 CFR 3.105(e), the provision that governs a reduction. And the note's last sentence says what replaces the 100 percent: if there has been no local recurrence or metastasis, rate on residuals. So the total evaluation does not end when treatment ends and it does not end on a calendar — it ends on an examination, and what follows it is a rating of what the disease and its treatment left behind. The second rule is the one most likely to be missed, because it is not printed under the code. 38 CFR 4.96(a) provides that ratings under diagnostic codes 6600 through 6817 and 6822 through 6847 will not be combined with each other, and then adds: where there is lung or pleural involvement, ratings under diagnostic codes 6819 and 6820 will not be combined with each other or with diagnostic codes 6600 through 6817 or 6822 through 6847. A single rating will be assigned under the diagnostic code which reflects the predominant disability, with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation. That is the answer to whether a residual lung condition can be rated alongside this code where the lung or pleura are involved: it cannot, and the route to a higher evaluation is the elevation the same paragraph describes. Where the residual is rated under one of the codes 38 CFR 4.96(d) governs — 6600, 6603, 6604, 6825 through 6833, and 6840 through 6845 — pulmonary function tests are required, with the exceptions that paragraph lists. 38 CFR 4.31 supplies a 0 percent under this code where the requirements for a compensable evaluation are not met.
- Diagnostic code
- 6819
- Rating schedule
- 38 CFR § 4.97
- Schedule levels
- 100%
How does the VA choose a rating level?
There is no higher or lower step inside this code: a rating decision either finds its criteria met or it does not. Where they are not met, 38 CFR § 4.31 assigns a 0% evaluation: service connection granted, at a level that does not pay.
EXPLORE THE PERCENTAGES
Malignant Neoplasms of the Respiratory System VA rating criteria (DC 6819)
This condition has one published rating level. Read the criteria, then explore the details and monthly pay.
These are published rating criteria. Selecting a level does not predict your VA decision.
IN THE REGULATION’S OWN WORDS
What 38 CFR also says about Malignant Neoplasms of the Respiratory System
The notes 38 CFR Part 4 prints with these criteria, quoted. They govern how the evaluation is made without being a rating level themselves.
- “Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.”DC 6819
BUILD YOUR EVIDENCE, ONE PIECE AT A TIME
Evidence for your Malignant Neoplasms of the Respiratory System claim
A long list feels easier when you have a place to start. Use this checklist to see what you have and what still needs gathering.
Check off what you’ve gathered. Progress stays on this page until you leave or refresh.
THE EXAM FORM
Which DBQ is used for Malignant Neoplasms of the Respiratory System?
VA's page says: “You can use these forms to submit medical evidence from your health care providers.”
Source: VA: Public Disability Benefits Questionnaires (DBQs), read September 18, 2026.
SMALL DETAILS. BETTER PREPARATION.
Preparing your Malignant Neoplasms of the Respiratory System claim
Start with the practical tips, then explore the common oversights. You don’t need to work through everything at once.
Practical tips for your claim5 tips
- 01
Put the treatment end date in the claim in writing. The six-month clock in DC 6819's note runs from the discontinuance of treatment, and that single date decides when the mandatory examination is due.
- 02
Build the residuals file while the 100 percent is running. The examination at six months determines the rating from that point, and it can only rate what is documented.
- 03
Ask for the elevation rather than a second rating. Where the lung or pleura are involved 38 CFR 4.96(a) assigns one rating under the predominant disability, and the same sentence provides for elevation to the next higher evaluation where the severity of the overall disability warrants it.
- 04
Read any proposed reduction against 38 CFR 3.105(e), which the note names by number as the provision governing a change in evaluation following the mandatory examination or any subsequent one.
- 05
Keep service connection and evaluation apart. Part 4 is the rating schedule and says nothing about how a disease was incurred; whether a respiratory cancer is presumptively service-connected is decided under 38 CFR part 3, not here.
C&P exam pitfalls to keep in mind4 tips
- 01
A six-month examination scheduled from the wrong date. The note runs six months from the DISCONTINUANCE of surgical, X-ray, antineoplastic chemotherapy or other therapeutic treatment, not from diagnosis and not from the last appointment of any kind.
- 02
An examination that records remission and stops there. The note replaces the 100 percent by rating on residuals where there has been no local recurrence or metastasis, so the residuals have to be examined and described, not just the absence of active disease.
- 03
Pulmonary function tests left undone at the residual examination. 38 CFR 4.96(d) requires PFTs for the codes a respiratory residual is usually rated under, lists the four situations that excuse them, and requires post-bronchodilator studies unless the pre-bronchodilator results were normal or the examiner says why they should not be done.
- 04
Ongoing therapy left out of the record. Treatment that has not been discontinued has not started the clock, and the note keeps the 100 percent running beyond the cessation of any of the procedures it lists.
Common filing mistakes5 tips
- 01
Arguing severity. DC 6819 has one criterion and one evaluation, so there is no tier to reach for while the code applies — site, stage and treatment do not move it.
- 02
Treating the end of treatment as the end of the rating. The note continues the 100 percent beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and replaces it only after a mandatory examination six months after discontinuance.
- 03
Claiming a separate respiratory rating alongside this one. Where there is lung or pleural involvement, 38 CFR 4.96(a) bars combining DC 6819 with DCs 6600 through 6817 or 6822 through 6847, or with DC 6820 — a single rating is assigned under the code reflecting the predominant disability.
- 04
Letting a reduction pass unanswered. A change in evaluation based on the mandatory examination or any subsequent one is subject to 38 CFR 3.105(e), which has its own notice and response procedure.
- 05
Filing nothing for the residuals. Where there has been no local recurrence or metastasis the note rates on residuals, and that evaluation can only be built from what the record documents.
When symptoms may first appear2 tips
- 01
The schedule describes no onset for this code. DC 6819 turns on the presence of a malignant neoplasm of the respiratory system, and its only timing rule runs the other way — forward from the end of treatment rather than back from a first symptom.
- 02
The one interval the regulation fixes is six months: the note makes a VA examination mandatory six months after any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure is discontinued, and the rating from that point is determined by that examination.
YOUR SERVICE STORY
Military jobs associated with Malignant Neoplasms of the Respiratory System
More by branch: Marines
LET’S CLEAR A FEW THINGS UP
Common questions about Malignant Neoplasms of the Respiratory System
Is Malignant Neoplasms of the Respiratory System a VA-rated disability?
Yes. The VA rates Malignant Neoplasms of the Respiratory System under VASRD diagnostic code 6819 (Respiratory System). DC 6819 is the respiratory system's cancer code, and it pays one evaluation: 100 percent. Its whole criterion is its own title — neoplasms, malignant, any specified part of respiratory system exclusive of skin growths — so site, stage and treatment do not move the percentage while the code applies. Two rules decide everything around it. The note ends the 100 percent not when treatment ends but at a mandatory VA examination six months after treatment is discontinued, and where there has been no local recurrence or metastasis the rating is then built on the residuals. And 38 CFR 4.96(a) says that where there is lung or pleural involvement a DC 6819 evaluation is not combined with the other respiratory codes: one rating is assigned, under whichever code reflects the predominant disability.
What VA disability rating can I get for Malignant Neoplasms of the Respiratory System?
Possible VA ratings for Malignant Neoplasms of the Respiratory System are 100%, 0%. The 0% level comes from 38 CFR 4.31, which assigns it wherever no compensable level is met. Examples: 100%: Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths.
What evidence helps prove Malignant Neoplasms of the Respiratory System for VA disability?
Strong evidence for a Malignant Neoplasms of the Respiratory System claim includes: A pathology report naming the malignancy and the part of the respiratory system it arose in. DC 6819's single criterion is the presence of a malignant neoplasm of that system, so the diagnosis is the whole of what the 100 percent rests on; Treatment records with dates — surgery, radiation, antineoplastic chemotherapy, or other therapeutic procedure. The note runs the 100 percent beyond the cessation of treatment and starts a six-month clock from discontinuance, so the date treatment stopped is the date that matters; The report of the mandatory VA examination six months after treatment is discontinued, which the note makes the basis for the rating from that point; Imaging and reports addressing local recurrence and metastasis, because the note's last sentence makes that the condition on which the rating moves to the residuals.
Which DBQ is used for Malignant Neoplasms of the Respiratory System?
VA's Respiratory Conditions (other than tuberculosis and sleep apnea) Disability Benefits Questionnaire (DBQ) is on its public list of DBQs. VA's page says: "You can use these forms to submit medical evidence from your health care providers."
What mistakes should veterans avoid when claiming Malignant Neoplasms of the Respiratory System?
Common pitfalls when filing for Malignant Neoplasms of the Respiratory System: Arguing severity. DC 6819 has one criterion and one evaluation, so there is no tier to reach for while the code applies — site, stage and treatment do not move it; Treating the end of treatment as the end of the rating. The note continues the 100 percent beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, and replaces it only after a mandatory examination six months after discontinuance; Claiming a separate respiratory rating alongside this one. Where there is lung or pleural involvement, 38 CFR 4.96(a) bars combining DC 6819 with DCs 6600 through 6817 or 6822 through 6847, or with DC 6820 — a single rating is assigned under the code reflecting the predominant disability; Letting a reduction pass unanswered. A change in evaluation based on the mandatory examination or any subsequent one is subject to 38 CFR 3.105(e), which has its own notice and response procedure.
When does the 100 percent rating for lung cancer end?
Not when treatment ends. DC 6819's note continues the 100 percent beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after that treatment is discontinued, a mandatory VA examination determines the appropriate disability rating from that point, and any change in evaluation based on that examination or any subsequent one is subject to 38 CFR 3.105(e), the provision that governs how a reduction is proposed and answered. The note's last sentence says what replaces it: if there has been no local recurrence or metastasis, rate on residuals. So the two dates that matter are the date treatment was discontinued and the date of the examination six months later.
Can I get a separate rating for COPD, asthma or sleep apnea alongside lung cancer?
Not where the lung or pleura are involved. 38 CFR 4.96(a) provides that ratings under diagnostic codes 6600 through 6817 and 6822 through 6847 will not be combined with each other, and then adds that where there is lung or pleural involvement, ratings under diagnostic codes 6819 and 6820 will not be combined with each other or with those codes either. A single rating is assigned under the diagnostic code which reflects the predominant disability, with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation. So the argument to make is for the elevation that paragraph provides, not for a second respiratory evaluation on top.
Official sources
- 38 CFR § 4.97, Schedule of ratings, respiratory system (Diagnostic Code 6819)
- 38 CFR § 4.31, zero percent evaluations
Criteria in quotation marks are the regulation’s own words; everything else on this page is Vetrify’s summary of it. The eCFR text is authoritative. See how Vetrify derives its numbers.
How these figures are checked: our methodology and the open dataset.
VA Calc: Disability Pay
Combine your ratings & see monthly pay on your iPhone · Works offline